SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...
(RTTNews) - Edwards Lifesciences Corp. (EW) on Tuesday said its SAPIEN M3 mitral valve replacement system received U.S. Food and Drug Administration (FDA) approval for the treatment of mitral ...
Edwards TAVR data has a strong showing at NY Valves 2026 amid intense industry competition from Abbott Laboratories and Medtronic.
The FDA has approved Edwards Lifesciences Corp.’s Sapien M3 transcatheter mitral valve replacement system. The U.S. approval, announced last week, comes eight months after the device received CE Mark ...
Edwards today presented new data at New York Valves 2026 supporting its transcatheter aortic valve replacement (TAVR) ...
Edwards Lifesciences’ SAPIEN M3 mitral valve replacement system has become the first transcatheter therapy utilizing a transseptal approach to snag FDA approval in the U.S. for the treatment of mitral ...
Edwards Lifesciences Corp.’s Sapien M3 secured CE mark for its Sapien M3 mitral valve replacement system for transfemoral treatment of patients with mitral valve disease who are ineligible for surgery ...
Review staff from the US Food and Drug Administration (FDA) said Edwards Lifesciences' Sapien Transcatheter Heart Valve (THV) met trial endpoints for safety and effectiveness for the treatment of high ...
Medtronic is emerging as the key rival to Edwards Lifesciences for a new type of heart valve Orange County is shaping up to be the stage for a two-horse race for a new type of heart valve. Last month, ...
Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which reinforce the company's ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果